Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
October 21 2022 - 6:05AM
Edgar (US Regulatory)
Filed
Pursuant to Rule 424(b)(5)
Registration
Statement No. 333-250966
PROSPECTUS
SUPPLEMENT
(to Prospectus dated December 4,
2020) |
|
This
prospectus supplement supplements and amends certain information contained in the prospectus supplement dated June 10, 2021 to the prospectus
dated December 4, 2020 (collectively, the “June 2021 Prospectus”), relating to the offer and sale of our common stock, par
value $0.01 per share (the “Common Stock”) through H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent,
in “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, pursuant to
the At the Market Offering Agreement with Wainwright dated as of June 10, 2021 (the “ATM Agreement”).
The
Common Stock is traded on The Nasdaq Capital Market under the symbol “MBOT”. The last sale price of the Common Stock on October
20, 2022 was $4.63 per share on The Nasdaq Capital Market. Under the June 2021 Prospectus, we initially registered up to
$10,000,000 of our Common Stock for offer and sale pursuant to the ATM Agreement. From June 10, 2021 through the date of this prospectus
supplement, we have not sold any shares of Common Stock under the June 2021 Prospectus.
The
purpose of this prospectus supplement is to suspend the ATM Agreement and to terminate the continuous offering by us under the June 2021
Prospectus effective on October 13, 2022. We will not make any sales of our Common Stock pursuant to the ATM Agreement unless and until
a new prospectus supplement is filed with the Securities and Exchange Commission; however, the ATM Agreement remains in full force
and effect.
The
date of this prospectus supplement is October 21, 2022.
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024